文献速递白血病淋巴瘤

TET1促进T细胞急性淋巴细胞白血病生长,并可通过PARP抑制拮抗

TET1 promotes growth of T-cell acute lymphoblastic leukemia and can be antagonized via PARP inhibition.
PubMed 文献 · Leukemia · 2020-05-15

在多种癌症中,表观遗传因子TET1在T细胞急性淋巴细胞白血病(T-ALL)中高表达,且对人工T-ALL细胞体内生长至关重要。小鼠敲除TET1或人工T细胞敲低TET1均不干扰正常T细胞增殖。TET1通过维持整体5-羟甲基胞嘧啶(5hmC)标记调控细胞周期、DNA修复基因及T-ALL相关癌基因,从而促进白血病生长。PARP酶参与在TET1启动子建立H3K4me3标记,PARP1与TET1蛋白相互作用;临床已批准的PARP抑制剂奥拉帕利可拮抗TET1表达、诱导5hmC标记丢失并拮抗T-ALL细胞白血病生长。

要点

  • TET1在T-ALL中高表达,对人工T-ALL细胞体内生长至关重要。
  • 小鼠敲除TET1或人工T细胞敲低TET1不干扰正常T细胞增殖。
  • 临床已批准的PARP抑制剂奥拉帕利可拮抗TET1表达并拮抗T-ALL细胞白血病生长。

核心结论

  • TET1在T-ALL中高表达并依赖其催化活性维持整体5hmC标记促进白血病生长,该生长相关作用可被临床已批准的PARP抑制剂奥拉帕利拮抗。

研究设计与样本

  • 研究在多种癌症类型中比较TET1表达,并采用小鼠敲除TET1、人工T细胞敲低TET1及TET1催化结构域过表达进行功能验证。

主要发现

  • 在多种癌症类型中,表观遗传因子TET1在T-ALL中高表达,且对人工T-ALL细胞体内生长至关重要。
  • 小鼠敲除TET1和人工T细胞敲低TET1均未扰动正常T细胞增殖,提示TET1表达对正常T细胞生长非必需。
  • TET1促进白血病生长依赖其催化特性维持整体5hmC标记,从而调控细胞周期、DNA修复基因及T-ALL相关癌基因。
  • 过表达Tet1催化结构域足以增加整体5hmC水平并增强T-ALL细胞体内白血病生长。
  • PARP酶在T-ALL患者中高表达,参与在TET1启动子建立H3K4me3标记,且PARP1与TET1蛋白相互作用。

临床怎么用

  • 临床已批准的PARP抑制剂奥拉帕利可拮抗TET1表达、诱导5hmC标记丢失并拮抗T-ALL细胞白血病生长,为该病开辟治疗途径。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

T-cell acute lymphoblastic leukemia (T-ALL) is an aggressive hematological cancer characterized by skewed epigenetic patterns, raising the possibility of therapeutically targeting epigenetic factors in this disease. Here we report that among different cancer types, epigenetic factor TET1 is highly expressed in T-ALL and is crucial for human T-ALL cell growth in vivo. Knockout of TET1 in mice and knockdown in human T cell did not perturb normal T-cell proliferation, indicating that TET1 expression is dispensable for normal T-cell growth. The promotion of leukemic growth by TET1 was dependent on its catalytic property to maintain global 5-hydroxymethylcytosine (5hmC) marks, thereby regulate cell cycle, DNA repair genes, and T-ALL associated oncogenes. Furthermore, overexpression of the Tet1-catalytic domain was sufficient to augment global 5hmC levels and leukemic growth of T-ALL cells in vivo. We demonstrate that PARP enzymes, which are highly expressed in T-ALL patients, participate in establishing H3K4me3 marks at the TET1 promoter and that PARP1 interacts with the TET1 protein. Importantly, the growth related role of TET1 in T-ALL could be antagonized by the clinically approved PARP inhibitor Olaparib, which abrogated TET1 expression, induced loss of 5hmC marks, and antagonized leukemic growth of T-ALL cells, opening a therapeutic avenue for this disease.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Bamezai S, Demir D, Pulikkottil AJ, et al. TET1 promotes growth of T-cell acute lymphoblastic leukemia and can be antagonized via PARP inhibition. Leukemia. 2020. PMID: 32409690. doi:10.1038/s41375-020-0864-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。